General MedicationsSUBCUTANEOUSStandard
ZEPBOUND
TIRZEPATIDE
Standard Dose
5MG/0.5ML (5MG/0.5ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ZEPBOUND is listed in Drugs@FDA under application 217806 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TIRZEPATIDE Form and strength SOLUTION;SUBCUTANEOUS - 5MG/0.5ML (5MG/0.5ML) Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2026-02-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZEPBOUND is listed in Drugs@FDA under application 217806 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TIRZEPATIDE Form and strength SOLUTION;SUBCUTANEOUS - 5MG/0.5ML (5MG/0.5ML) Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2026-02-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.